Business
Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress
Ibezapolstat is currently enrolling in a Phase 2b trial for C. difficile infection in U.S. centers across the country and nearing its goal to reach a targeted
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"Ibezapolstat is currently enrolling in a Phase 2b trial for C. difficile infection in U.S. centers across the country and nearing its goal to reach a targeted 36 patients at which point an Interim Analysis of the unblinded primary clinical endpoint and safety data will be reviewed by an Independent Data Monitoring CommitteeIbezapolstat has received FDA QIDP and Fast-Track DesignationAlso presented was an update on the Company's pre-clinical antibiotic program in Lead Optimization stage for systemic gram-positive bacterial infections, including Acute Bacterial Skin and Skin Structure Infections caused by MRSAThe company's preclinical pipeline also targets systemic infections caused by other gram-positive bacteria such as VRE and DRSP which are expected to be QIDP and Fast-Track eligible as product candidates advance in developmentSTATEN ISLAND, N.Y., Sept. 12, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (\"Acurx\" or the \"Company\"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that a presentation was given by Acurx Executive Chairman, Robert J. DeLuccia, at the World Antimicrobial Resistance Scientific Congress on September 7, 2023. In his presentation at the Innovation Showcase session, he highlighted that the Company anticipates completing enrollment of the 36 patients required for an interim review of the Phase 2b data by the Independent Data Monitoring Committee (IDMC) in the coming months.\n\nMr. DeLuccia also presented an update on the Company's preclinical GPSS™ (Gram Positive Selective Spectrum) program for systemic oral and IV treatment of other gram-positive infections including MRSA, VRE and DRSP. Mr. DeLuccia summarized the progress stating that \"Our potential lead compound meets Theurezbacher's criteria for antibiotic innovation in that it is a new chemical class, has novel mechanism and bacterial target, and has not shown cross-resistance in early in vitro microbiology studies.\" He further stated: \"Having established clinical validation of the pol IIIC bacterial target in a Ph2a proof-of-principal trial showing 100% cure of C. difficile Infection, with no recurrence after 30 days' follow up, we have made substantial progress toward lead compound selection of our gram-positive IV and oral compound...